Cascadian Therapeutics Inc (CASC.OQ)

CASC.OQ on NASDAQ Stock Exchange Global Select Market

17 Jan 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Cascadian Therapeutics Files For Mixed Shelf Of Up To $250 Mln
Saturday, 30 Dec 2017 

Dec 29 (Reuters) - Cascadian Therapeutics Inc ::CASCADIAN THERAPEUTICS FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING.  Full Article

Cascadian Therapeutics reports Q3 loss per share $0.28
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Cascadian Therapeutics Inc ::Cascadian Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.28.Q3 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.Cascadian therapeutics - ‍ cash, cash equivalents and investments totaled $113.0 million as of Sept 30, 2017, compared to $62.8 million at Dec 31, 2016​.Cascadian Therapeutics Inc - ‍ cash used in operations for 2017 is expected to be approximately $50.0 million to $54.0 million​.  Full Article

Cascadian Therapeutics reports Q2 loss per share $0.26
Tuesday, 9 Aug 2016 

Cascadian Therapeutics Inc : Cascadian Therapeutics reports second quarter 2016 financial results and provides corporate update . Q2 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.26 . "Early clinical results with ont-380 when combined with T-DM1 or Capecitabine have suggested a favorable safety and tolerability profile" .Estimates that its cash, cash-equivalents and investments will be sufficient to fund operations for at least next 12 months.  Full Article

Cascadian Therapeutics receives Ont-380 fast track designation from FDA for treatment of advanced breast cancer
Wednesday, 29 Jun 2016 

Cascadian Therapeutics Receives Ont : Says company is actively recruiting patients for a randomized, double-blind, placebo-controlled phase 2 study .380 fast track designation from FDA for the treatment of advanced her2+ metastatic breast cancer.  Full Article

Oncothyreon says company is changing its name to Cascadian Therapeutics
Wednesday, 8 Jun 2016 

: Oncothyreon Inc says company is changing its name to cascadian therapeutics, inc .Oncothyreon Inc says will trade on nasdaq global select market under new ticker symbol "CASC," effective at market open on June 9, 2016.  Full Article

Oncothyreon says may issue and sell shares with sales proceeds of up to $50 mln
Friday, 3 Jun 2016 

Oncothyreon Inc : Agreement to sell shares of company's common stock, par value $0.0001 per share, having aggregate sales proceeds of up to $50 million .On June 2, 2016, co entered into sales agreement with cowen and company to sell shares of co's common stock, par value $0.0001/share.  Full Article

Oncothyreon Q1 loss per share $0.14
Tuesday, 10 May 2016 

Oncothyreon Inc : Oncothyreon Inc says oncothyreon currently expects operating expenses in 2016 to be higher than in 2015 . Oncothyreon inc says oncothyreon currently expects cash used in operations in 2016 to be approximately $38.0 million to $40.0 million . Oncothyreon reports first quarter 2016 financial results & provides corporate update . Q1 loss per share $0.14 .Q1 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Oncothyreon Appoints Scott D. Myers Chief Executive Officer
Tuesday, 29 Mar 2016 

Oncothyreon Inc:Says appointment of Scott D. Myers as President, Chief Executive Officer and a member of the Board of Directors, effective April 4, 2016.  Full Article

BRIEF-Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver From The European Medicines Agency

* CASCADIAN THERAPEUTICS RECEIVES PEDIATRIC INVESTIGATION PLAN WAIVER FROM THE EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)